Literature DB >> 20185587

Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.

Lisa M Sedger1, Arna Katewa, Ann K Pettersen, Sarah R Osvath, Geoff C Farrell, Graeme J Stewart, Linda J Bendall, Stephen I Alexander.   

Abstract

To delineate the relative roles of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand in lymphocyte biology and lymphoproliferative disease, we generated mice defective in both molecules. B6.GT mice develop severe polyclonal lymphoproliferative disease because of accumulating CD3(+)CD4(-)CD8(-)B220(+) T cells, CD4(+) and CD8(+) T cells, and follicular B cells, and mice die prematurely from extreme lymphocytosis, thrombocytopenia, and hemorrhage. Accumulating lymphocytes resembled antigen-experienced lymphocytes, consistent with the maximal resistance of B6.GT CD4(+) and CD8(+) T cell to activation-induced cell death. More specifically, we show that TRAIL contributes to Fas ligand-mediated activation-induced cell death and controls lymphocyte apoptosis in the presence of interferon-gamma once antigen stimulation is removed. Furthermore, dysregulated lymphocyte homeostasis results in the production of anti-DNA and rheumatoid factor autoantibodies, as well as antiplatelet IgM and IgG causing thrombocytopenia. Thus, B6.GT mice reveal new roles for TRAIL in lymphocyte homeostasis and autoimmune lymphoproliferative syndromes and are a model of spontaneous idiopathic thrombocytopenia purpura secondary to lymphoproliferative disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185587      PMCID: PMC2858490          DOI: 10.1182/blood-2009-11-255497

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells.

Authors:  R Ahmad; J Menezes; L Knafo; A Ahmad
Journal:  J Leukoc Biol       Date:  2001-01       Impact factor: 4.962

Review 2.  Apoptosis signaling.

Authors:  A Strasser; L O'Connor; V M Dixit
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

3.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.

Authors:  S E Straus; E S Jaffe; J M Puck; J K Dale; K B Elkon; A Rösen-Wolff; A M Peters; M C Sneller; C W Hallahan; J Wang; R E Fischer; C E Jackson; A Y Lin; C Bäumler; E Siegert; A Marx; A K Vaishnaw; T Grodzicky; T A Fleisher; M J Lenardo
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells.

Authors:  K Takeda; Y Hayakawa; M J Smyth; N Kayagaki; N Yamaguchi; S Kakuta; Y Iwakura; H Yagita; K Okumura
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

5.  Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis.

Authors:  B Hilliard; A Wilmen; C Seidel; T S Liu; R Göke; Y Chen
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

6.  BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes.

Authors:  Philippe Bouillet; Jared F Purton; Dale I Godfrey; Li-Chen Zhang; Leigh Coultas; Hamsa Puthalakath; Marc Pellegrini; Suzanne Cory; Jerry M Adams; Andreas Strasser
Journal:  Nature       Date:  2002-02-21       Impact factor: 49.962

7.  Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype.

Authors:  H Körner; E Cretney; P Wilhelm; J M Kelly; M Röllinghoff; J D Sedgwick; M J Smyth
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

8.  Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Authors:  Kazuyoshi Takeda; Mark J Smyth; Erika Cretney; Yoshihiro Hayakawa; Nobuhiko Kayagaki; Hideo Yagita; Ko Okumura
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Authors:  M J Smyth; E Cretney; K Takeda; R H Wiltrout; L M Sedger; N Kayagaki; H Yagita; K Okumura
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease.

Authors:  Andrew Kovalenko; Jin-Chul Kim; Tae-Bong Kang; Akhil Rajput; Konstantin Bogdanov; Oliver Dittrich-Breiholz; Michael Kracht; Ori Brenner; David Wallach
Journal:  J Exp Med       Date:  2009-08-31       Impact factor: 14.307

View more
  11 in total

Review 1.  RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts.

Authors:  Douglas R Green; Andrew Oberst; Christopher P Dillon; Ricardo Weinlich; Guy S Salvesen
Journal:  Mol Cell       Date:  2011-10-07       Impact factor: 17.970

Review 2.  Multiple mechanisms of immune suppression by B lymphocytes.

Authors:  Matthew W Klinker; Steven K Lundy
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

3.  Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Authors:  F Fioredda; E Cappelli; A Mariani; A Beccaria; E Palmisani; A Grossi; I Ceccherini; R Venè; C Micalizzi; M Calvillo; F Pierri; I Mancini; F Peyvandi; F Corsolini; C Dufour; M Miano
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Authors:  Rumani Singh; Anthony Letai; Kristopher Sarosiek
Journal:  Nat Rev Mol Cell Biol       Date:  2019-03       Impact factor: 94.444

5.  MLKL and FADD Are Critical for Suppressing Progressive Lymphoproliferative Disease and Activating the NLRP3 Inflammasome.

Authors:  Xixi Zhang; Cunxian Fan; Haiwei Zhang; Qun Zhao; Yongbo Liu; Chengxian Xu; Qun Xie; Xiaoxia Wu; Xianjun Yu; Jianke Zhang; Haibing Zhang
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

Review 6.  Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.

Authors:  Etienne Leveille; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

Review 7.  TRAIL modulates the immune system and protects against the development of diabetes.

Authors:  Fleur Bossi; Stella Bernardi; Giorgio Zauli; Paola Secchiero; Bruno Fabris
Journal:  J Immunol Res       Date:  2015-02-18       Impact factor: 4.818

Review 8.  Stress Management: Death Receptor Signalling and Cross-Talks with the Unfolded Protein Response in Cancer.

Authors:  Elodie Lafont
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

9.  TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes.

Authors:  Julian Staniek; Raquel Lorenzetti; Bianca Heller; Iga Janowska; Pascal Schneider; Susanne Unger; Klaus Warnatz; Maximilian Seidl; Nils Venhoff; Jens Thiel; Cristian Roberto Smulski; Marta Rizzi
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

10.  Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment.

Authors:  Manuela Liguori; Chiara Buracchi; Fabio Pasqualini; Francesca Bergomas; Samantha Pesce; Marina Sironi; Fabio Grizzi; Alberto Mantovani; Cristina Belgiovine; Paola Allavena
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.